A Phase II, Open, Single-center Study of PD-1 Antibody and PARP Inhibitor as Consolidation Treatment for Patients With Extensive Stage Small Cell Lung Cancer Who Have Not Progressed After First-line Treatment
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2021).
- 10 Mar 2021 New trial record